wikidoc - Recent changes [en]

File:Datopotamab display panel.jpeg

2026-04-28T14:09:42Z

Anum Ijaz uploaded File:Datopotamab display panel.jpeg

New page

Sandbox

2026-04-28T01:40:03Z

← Older revision		Revision as of 01:40, 28 April 2026
Line 30:		Line 30:
	* [[Statin\|Statins]]: high-intensity statin therapy for atherosclerotic TAA		* [[Statin\|Statins]]: high-intensity statin therapy for atherosclerotic TAA

	== 2022 ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease <ref name="pmid36334952">{{cite journal \|vauthors=Isselbacher EM, Preventza O, Hamilton Black Iii J, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A, Fanola CL, Girardi LN, Hicks CW, Hui DS, Jones WS, Kalahasti V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Ross EG, Schermerhorn ML, Times SS, Tseng EE, Wang GJ, Woo YJ \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=J Am Coll Cardiol \|volume=80 \|issue=24 \|pages=e223–e393 \|date=December 2022 \|pmid=36334952 \|pmc=9860464 \|doi=10.1016/j.jacc.2022.08.004 \|url=}}</ref> <ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC">{{cite web \|url=https://www.jacc.org/doi/10.1016/j.jacc.2022.08.004 \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC \|format= \|work= \|accessdate=}}</ref> ==		==2022 ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease <ref name="pmid36334952">{{cite journal \|vauthors=Isselbacher EM, Preventza O, Hamilton Black Iii J, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A, Fanola CL, Girardi LN, Hicks CW, Hui DS, Jones WS, Kalahasti V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Ross EG, Schermerhorn ML, Times SS, Tseng EE, Wang GJ, Woo YJ \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=J Am Coll Cardiol \|volume=80 \|issue=24 \|pages=e223–e393 \|date=December 2022 \|pmid=36334952 \|pmc=9860464 \|doi=10.1016/j.jacc.2022.08.004 \|url=}}</ref> <ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC">{{cite web \|url=https://www.jacc.org/doi/10.1016/j.jacc.2022.08.004 \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC \|format= \|work= \|accessdate=}}</ref>==

	=== Multidisciplinary Aortic Team and Shared Decision-Making<ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC" /> ===		=== Multidisciplinary Aortic Team and Shared Decision-Making<ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC" /> ===
Line 185:		Line 185:

	== '''References''' ==		== '''References''' ==
			<references />

Datopotamab deruxtecan-dlnk

2026-04-28T00:58:04Z

Show changes

Sandbox

2026-04-28T00:07:58Z

Multidisciplinary Aortic Team and Shared Decision-Making[2]

Show changes

Datopotamab deruxtecan-dlnk

2026-04-27T23:52:27Z

Sandbox

2026-04-27T23:15:44Z

Show changes

Atrial fibrillation

2026-04-27T21:51:47Z

Rhythm Control

Show changes

User:Hasnain Ali

2026-04-27T20:24:40Z

← Older revision		Revision as of 20:24, 27 April 2026
Line 10:		Line 10:
	I create original content on my areas of interest and refresh older chapters to keep the medical information current.		I create original content on my areas of interest and refresh older chapters to keep the medical information current.

	* Resident ~~Medical Officer with Dept. of Neurology~~, Liaquat University hospital Hyderabad/Jamshoro, Pakistan.		* Resident, Liaquat University hospital Hyderabad/Jamshoro, Pakistan.

	I provide inpatient and outpatient neurological care, managing up to 5 inpatients daily and around 30 clinic and emergency patients per week. Alongside clinical duties, I participated in multidisciplinary academic activities and contributed to research through systematic data collection and documentation.		I provide inpatient and outpatient neurological care, managing up to 5 inpatients daily and around 30 clinic and emergency patients per week. Alongside clinical duties, I participated in multidisciplinary academic activities and contributed to research through systematic data collection and documentation.

Industrial and organizational psychology

2026-04-27T20:07:19Z

Career calling

← Older revision		Revision as of 20:07, 27 April 2026
(4 intermediate revisions by the same user not shown)
Line 18:		Line 18:
	* [[Empowerment(psychology)\|Empowerment]]		* [[Empowerment(psychology)\|Empowerment]]
	* [[Engagement (psychology)\|Engagement]]		* [[Engagement (psychology)\|Engagement]]
			* [[Career calling]]
	* [[Job satisfaction]]		* [[Job satisfaction]]
	* [[Burnout (psychology)\|Burnout]]		* [[Burnout (psychology)\|Burnout]]
Line 63:		Line 64:
	* "Would you say you are thriving or struggling with the following types of bonds or relationships at work?"		* "Would you say you are thriving or struggling with the following types of bonds or relationships at work?"

	A separate body of research has emerged more recently that gives a broader definition to thriving, but does not cite the above research that has used factor analysis to identify core features~~<ref>~~<ref name="pmid28913621">{{cite journal\| author=Brady KJS, Trockel MT, Khan CT, Raj KS, Murphy ML, Bohman B et al.\| title=What Do We Mean by Physician Wellness? A Systematic Review of Its Definition and Measurement. \| journal=Acad Psychiatry \| = 2017 \| volume= \| issue= \| pages= \| pmid=28913621 \| doi=10.1007/s40596-017-0781-6 \| pmc= \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28913621 }} </ref><ref>Feeney, B. C., & Collins, N. L. (2015). A new look at social support: A theoretical perspective on thriving through relationships. Personality and Social Psychology Review, 19(2), 113-147. {{doi\|10.1177/1088868314544222}}</ref>.		A separate body of research has emerged more recently that gives a broader definition to thriving, but does not cite the above research that has used factor analysis to identify core features<ref name="pmid28913621">{{cite journal\| author=Brady KJS, Trockel MT, Khan CT, Raj KS, Murphy ML, Bohman B et al.\| title=What Do We Mean by Physician Wellness? A Systematic Review of Its Definition and Measurement. \| journal=Acad Psychiatry \| = 2017 \| volume= \| issue= \| pages= \| pmid=28913621 \| doi=10.1007/s40596-017-0781-6 \| pmc= \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28913621 }} </ref><ref>Feeney, B. C., & Collins, N. L. (2015). A new look at social support: A theoretical perspective on thriving through relationships. Personality and Social Psychology Review, 19(2), 113-147. {{doi\|10.1177/1088868314544222}}</ref>.

	==== Importance====		==== Importance====
Line 177:		Line 178:
	* Emotional: I feel energetic at my job; I am enthusiastic in my job		* Emotional: I feel energetic at my job; I am enthusiastic in my job
	* Cognitive: At work, I focus a great deal of attention on my job; At work, I am absorbed by my job		* Cognitive: At work, I focus a great deal of attention on my job; At work, I am absorbed by my job

			===Career calling ===
			Career calling has various definitions, a more recent definition by Rosso and Wrzesniewski is, "meaningful beckoning toward work activities that are morally, socially, and personally significant"<ref name="Rosso2010">{{cite journal \| last1=Rosso \| first1=Brent D. \| last2=Dekas \| first2=Kathryn H. \| last3=Wrzesniewski \| first3=Amy \| title=On the meaning of work: A theoretical integration and review \| journal=Research in Organizational Behavior \| volume=30 \| date=2010 \| doi=10.1016/j.riob.2010.09.001 \| pages=91–127 \| url=https://linkinghub.elsevier.com/retrieve/pii/S0191308510000067 \| access-date=2026-04-27}}</ref>. calling can be measured with<ref name="Dik2012">{{cite journal \| last1=Dik \| first1=Bryan J. \| last2=Eldridge \| first2=Brandy M. \| last3=Steger \| first3=Michael F. \| last4=Duffy \| first4=Ryan D. \| title=Development and Validation of the Calling and Vocation Questionnaire (CVQ) and Brief Calling Scale (BCS) \| journal=Journal of Career Assessment \| volume=20 \| issue=3 \| date=2012 \| issn=1069-0727 \| doi=10.1177/1069072711434410 \| pages=242–263 \| url=https://journals.sagepub.com/doi/10.1177/1069072711434410 \| access-date=2026-04-27}}</ref>:
			# I have a calling to my current line of work.
			# I have a good understanding of my calling as it applies to my career.

			Career calling can be promoted by a career calling climate at work<ref name="Chen 2025">{{cite journal \| last1=Chen \| first1=Jiatian \| last2=May \| first2=Douglas R. \| last3=Schwoerer \| first3=Catherine E. \| title=Career calling climate: The development and validation of a scale for a new construct \| journal=Journal of Management & Organization \| volume=31 \| issue=4 \| date=2025 \| issn=1833-3672 \| doi=10.1017/jmo.2023.16 \| pages=1688–1707 \| url=https://www.cambridge.org/core/product/identifier/S1833367223000160/type/journal_article \| access-date=2026-04-27}}</ref>.

			Calling may increase engagement at work, especially is organizational commitment is present<ref name="Cao2019">{{cite journal \| last1=Cao \| first1=Yudi \| last2=Liu \| first2=Jingying \| last3=Liu \| first3=Kejia \| last4=Yang \| first4=Mengyu \| last5=Liu \| first5=Yanhui \| title=The mediating role of organizational commitment between calling and work engagement of nurses: A cross-sectional study \| journal=International Journal of Nursing Sciences \| volume=6 \| issue=3 \| date=2019-07-10 \| issn=2352-0132 \| pmid=31508452 \| pmc=6722477 \| doi=10.1016/j.ijnss.2019.05.004 \| pages=309–314 \| url=https://pubmed.ncbi.nlm.nih.gov/31508452 \| access-date=2026-04-27}}</ref> as measured by the organizational commitment scale (OCS)<ref name="Allen2011">{{cite journal \| last1=Allen \| first1=Natalie J. \| last2=Meyer \| first2=John P. \| title=The measurement and antecedents of affective, continuance and normative commitment to the organization \| journal=Journal of Occupational Psychology \| volume=63 \| issue=1 \| date=1990 \| issn=0305-8107 \| doi=10.1111/j.2044-8325.1990.tb00506.x \| pages=1–18 \| url=https://bpspsychub.onlinelibrary.wiley.com/doi/10.1111/j.2044-8325.1990.tb00506.x \| access-date=2026-04-27}}</ref>.

	===Satisfaction===		===Satisfaction===

Atrial fibrillation overview

2026-04-27T17:15:33Z

Show changes

Supraventricular tachycardia

2026-04-27T17:08:57Z

Show changes

← Older revision		Revision as of 23:52, 27 April 2026
Line 45:		Line 45:
	DATROWAY can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.		DATROWAY can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.

	Locally Advanced or Metastatic NSCLC		'''Locally Advanced or Metastatic NSCLC''

	In the pooled safety population of 484 patients with NSCLC from TROPION-Lung01, TROPION-Lung05, and TROPION-PanTumor01 ~~[see Adverse Reactions (6.1)]~~, ILD/pneumonitis occurred in 7% of patients treated with DATROWAY, including 0.6% of patients with Grade 3 and 0.4% with Grade 4. There were 8 (1.7%) fatal cases. The median time to onset for ILD was 1.4 months (range: 0.2 months to 9 months). Eleven patients (2.3%) had DATROWAY withheld and 20 patients (4.1%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 79% (26/33) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 45% of patients.		In the pooled safety population of 484 patients with NSCLC from TROPION-Lung01, TROPION-Lung05, and TROPION-PanTumor01, ILD/pneumonitis occurred in 7% of patients treated with DATROWAY, including 0.6% of patients with Grade 3 and 0.4% with Grade 4. There were 8 (1.7%) fatal cases. The median time to onset for ILD was 1.4 months (range: 0.2 months to 9 months). Eleven patients (2.3%) had DATROWAY withheld and 20 patients (4.1%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 79% (26/33) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 45% of patients.

	Unresectable or Metastatic Breast Cancer		Unresectable or Metastatic Breast Cancer
Line 86:		Line 86:


	The safety of DATROWAY was evaluated in 125 patients with EGFR-mutated NSCLC who received DATROWAY 6 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity in TROPION-Lung05 and TROPION-Lung01 ~~[see Clinical Studies (14.1)]~~ as well as TROPION-PanTumor01 (NCT03401385). Among these patients, the median duration of treatment was 6.1 months (range 0.7 months to 41.7 months).		The safety of DATROWAY was evaluated in 125 patients with EGFR-mutated NSCLC who received DATROWAY 6 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity in TROPION-Lung05 and TROPION-Lung01 as well as TROPION-PanTumor01 (NCT03401385). Among these patients, the median duration of treatment was 6.1 months (range 0.7 months to 41.7 months).

	The median age was 63 years (range: 36 to 81), 56% of patients were <65 years, 62% of patients were female; 66% were Asian, 26% were White, 0.8% were Black, 6% were other races; and 2.4% were of Hispanic ethnicity.		The median age was 63 years (range: 36 to 81), 56% of patients were <65 years, 62% of patients were female; 66% were Asian, 26% were White, 0.8% were Black, 6% were other races; and 2.4% were of Hispanic ethnicity.
Line 161:		Line 161:

	Reconstitute immediately before dilution.		Reconstitute immediately before dilution.
	More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted DATROWAY solution required, and the number of vial(s) of DATROWAY needed ~~[see Dosage and Administration (2.2)]~~.		More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted DATROWAY solution required, and the number of vial(s) of DATROWAY needed.
	Reconstitute each 100 mg vial using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection into each vial to obtain a final concentration of 20 mg/mL.		Reconstitute each 100 mg vial using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection into each vial to obtain a final concentration of 20 mg/mL.
	Swirl the vial gently until completely dissolved. Do not shake.		Swirl the vial gently until completely dissolved. Do not shake.
Line 286:		Line 286:
	Interstitial Lung Disease/Pneumonitis		Interstitial Lung Disease/Pneumonitis

	Inform patients of the risks of severe or fatal ILD. Advise patients to contact their healthcare provider immediately for any of the following: cough, shortness of breath, fever, or other new or worsening respiratory symptoms ~~[see Warnings and Precautions (5.1)]~~.		Inform patients of the risks of severe or fatal ILD. Advise patients to contact their healthcare provider immediately for any of the following: cough, shortness of breath, fever, or other new or worsening respiratory symptoms.
	Ocular Adverse Reactions		Ocular Adverse Reactions

	Inform patients about the need for eye exams at initiation and during treatment with DATROWAY ~~[see Dosage and Administration (2.3)]~~.		Inform patients about the need for eye exams at initiation and during treatment with DATROWAY .
	Advise patients to contact their healthcare provider if they experience any eye symptoms.		Advise patients to contact their healthcare provider if they experience any eye symptoms.
	Advise patients to use preservative-free lubricating eye drops several times daily and to avoid use of contact lenses during treatment with DATROWAY.		Advise patients to use preservative-free lubricating eye drops several times daily and to avoid use of contact lenses during treatment with DATROWAY.